1.7 semaglutide to tirzepatide vs Tirzepatide: 7 Powerful Differences Switching from Semaglutide to Tirzepetide

[1] Patients should be counseled about potential gastrointestinal symptoms related to delayed gastric emptying, particularly during dose escalation

Nutrition and Dietary Supplements

It was first approved by the FDA in 1959

Some people fine-tune: e.g., a patient might feel best on 1.7 mg Wegovy and not go to 2.4 because 1.7 mg curbs appetite adequately with tolerable side effects and 2.4 mg adds too much nausea

Any severe or persistent vomiting, signs of dehydration, severe abdominal pain, or symptoms suggestive of pancreatitis (persistent severe abdominal pain radiating to the back) warrant immediate medical evaluation and possible suspension of treatment